In the present study of patients with BMD, treatment with a phosphodiesterase 5 (PDE5) inhibitor resulted in a significant increase in the BOLD signal in somatosensory and visual areas, which indicates that the NO‐cGMP cascade could be involved (Lindberg et al., 2017). Here, PDE5A is linked to Becker muscular dystrophy.